JOON WOO LEE: Open Payments
NPI 1609397066 · EAST CHICAGO, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,832 in 142 payments from 15 companies in 2025. Trend: 2023 $2,744 · 2024 $2,672 · 2025 $2,832
Food & beverage: $2,731Education: $101
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 16 | $385 |
| Neurocrine BioSciences, Inc. | 16 | $359 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $335 |
| E.R. Squibb & Sons, L.L.C. | 17 | $298 |
| ABBVIE INC. | 14 | $282 |
| Otsuka America Pharmaceutical, Inc. | 14 | $235 |
| Vanda Pharmaceuticals Inc. | 11 | $226 |
| Alkermes, Inc. | 11 | $213 |
| Lundbeck LLC | 13 | $206 |
| Axsome Therapeutics, Inc. | 5 | $111 |
Products named: INGREZZA, CAPLYTA, COBENFY, VRAYLAR, UZEDY, FANAPT, ARISTADA, REXULTI.
Industry payments across IN — which companies pay providers there.
